HERON and Linkou Chang Gung Memorial Hospital Sign Letter of Intent for BNCT Clinical Trial Collaboration in Breast Cancer

HERON and Chang Gung Memorial Hospital, Linkuo

Sign Letter of Intent for BNCT Clinical Trial Collaboration in Breast Cancer 

HERON Neutron Medical Corp. has signed a Letter of Intent (LOI) with Linkou Chang Gung Memorial Hospital (CGMH), under the Chang Gung Medical Foundation, to establish a collaborative framework for a clinical trial program evaluating the application of Boron Neutron Capture Therapy (BNCT) in breast cancer.

 As one of Taiwan's leading medical centers, CGMH, Linkuo has long been committed to cancer treatment, clinical research, and the development of innovative medical technologies. The institution possesses extensive experience in conducting clinical trials and access to substantial patient resources. HERON, on the other hand, focuses on the development and advancement of accelerator-based BNCT (AB-BNCT) systems and related technologies, with strong capabilities in system integration and clinical application.

 Given the existing unmet medical needs in certain breast cancer clinical settings, both parties will jointly evaluate the safety, feasibility, and preliminary efficacy of BNCT in breast cancer patients. The results will serve as a foundation for future expanded studies and potential clinical applications.

 This collaboration aims to integrate the clinical research strengths of a leading medical center with HERON's AB-BNCT technological advantages to generate scientifically validated clinical evidence. Through systematic clinical trial design and execution, the project seeks to validate the potential of advanced radiation therapy technologies in specific clinical scenarios, supporting future expansion into broader clinical research, indication development, and real-world clinical adoption. Ultimately, this initiative is expected to enhance Taiwan's capabilities in the field of innovative cancer treatment.